95;question probabilist opinion differ individu aggreg form group opinion controversi assumpt pretti common ground group bayesian represent group opinion uniqu probabl distribut madanski lehrer wagner mcconway journal american statist associ bordley manag scienc genest et al annal statist genest zidek statist scienc mongin journal econom theori clemen winkler risk analysi dietrich list herzberg theori decis argu assumpt order extend canon mathemat framework pool cover pool imprecis probabl ip employ set valu pool function gener common pool axiom accordingli proof concept ip construct satisfi number central pool axiom jointli satisfi standard pool recip pain trivial follow levi synthes argu ip model admit better philosoph motiv model ration consensu
21;congenit nonunion clavicl well known patholog children posttraumat nonunion rare entiti nonunion open reduct intern fixat clavicl fractur except pediatr popul report patient present posttraumat pseudarthrosi clavicl surgic treatment pseudarthrosi resect defect bridg iliac crest autograft supplement bone morphogenet protein fix elast stabl intramedullari nail procedur offer stabil achiev fractur consolid safe altern plate clavicl nonunion
72;cyclin depend kinas cdk inhibitor revolution treatment landscap hormon receptor posit hr human epiderm growth factor receptor neg her metastat breast cancer impress efficaci safeti profil cytopenia main advers event predict manag here report case cdk inhibitor induc vitiligo lik lesion vitiligo vitiligo lik lesion rare advers event case report literatur year old femal patient diagnos initi early stag right breast cancer hr her treat breast conserv surgeri follow chemotherapi radiotherapi hormon therapi year later develop metastat diseas hilar lymph node multipl skelet site includ left scapula left shoulder left iliac bone dorsal vertebra treat ribociclib letrozol treatment develop hypopig lesion involv hand feet face describ vitiligo lik lesion cdk inhibitor induc vitiligo rare unpredict advers event case report highlight rariti advers event dilemma relat optim treatment decis relat continu hold switch cdk inhibitor
49;radium ra prolong surviv improv qualiti life men metastat castration resist prostat cancer mcrpc bone howev compar mcrpc therapi use ra come uniqu challeng henc aim identifi ra util pattern real world condit factor predict treatment complet outcom retrospect chart analysi mcrpc patient identifi receiv ra outsid clinic trial access program januari octob cancer centr ontario main outcom studi ra complet rate reason earli treatment discontinu overal surviv surviv differ patient complet ra therapi versu patient receiv cycl ra addit patient diseas characterist analys identifi predictor treatment complet surviv cohort patient pretreat abirateron and or enzalutamid half receiv docetaxel ra complet rate actuari median surviv month main reason earli ra discontinu diseas progress ra non complet associ poorer outcom median surviv month versu month men complet ra p lymph node metastas high baselin prostate specif antigen psa independ predictor earli treatment discontinu multivari cox proport hazard model reveal earli ra discontinu baselin anemia high psa prior skeletal rel event viscer metastas refer centr ra therapi predictor wors outcom despit lower complet rate observ clinic trial condit real world result achiev ra encourag prospect valid predict patient diseas characterist identifi cohort instrument identifi mcrpc patient like complet benefit ra therapi
19;scholar interest relationship social context health recent turn attent upstream understand polit social econom institut shape distribut life chanc context compar minor health inequ european countri n investig arrangements welfar state effort immigr incorpor policies influ distribut health health inequ examin measur health seven wave european social survey result seri multilevel mixed effect model minor health inequ vari context persist account socioeconom differ cross level interact result welfar state effort associ better health group unrel level inequ group contrast polici aim protect minor discrimin correl smaller rel health inequ
44;caus dispar biodivers region fundament question biogeographi ecolog evolutionari biolog evolutionari biogeograph process speciat extinct dispers directli determin speci rich pattern studi use integr phylogenet approach howev strikingli high rich east asia rel northern hemispher region remain poorli understood perspect here time test gener hypothes older colon time faster diversif rate explain pattern use plant tribe lysimachiea primulacea model system gener new time calibr phylogeni lysimachiea gene speci estim colon time diversif rate region test rel import factor explain region rich pattern time diversif rate explain rich pattern region lysimachiea instead new index combin factor explain global rich pattern group high east asian biodivers base result lysimachiea suggest high rich plant east asia explain combin older colon time faster diversif rate region
102;plant function trait regul ecosystem function littl known co occur gradient land use edaph condit influenc express test gradient log disturb soil properti relat community weight mean trait log old growth tropic forest borneo studi physic chemic physiolog trait tree speci ha plot measur long term soil nutrient suppli plant avail nutrient log plot greater valu trait drive carbon captur growth whilst old growth forest greater valu structur persist trait disturb primari driver trait express soil nutrient explain statist independ axi variat link leaf size nutrient concentr soil characterist influenc trait express nutrient avail nutrient pool ph find trait dissimilar respons land use soil resourc avail provid robust evid need consid abiot context log predict plant function divers human modifi tropic forest detect independ axe facilit measur function trait examin previou studi
25;non smal cell lung cancer nsclc largest type lung cancer lc higher mortal rate circular rna circrna shown play import role cancer progress therefor studi explor function hsa circ nsclc express level hsa circ microrna p mir p forkhead box p foxp determin quantit real tim polymeras chain reaction qrt pcr ribonucleas r rnase r actinomycin d actd use verifi authent stabil hsa circ cell count kit cck flow cytometri transwel assay use evalu abil prolifer apoptosi migrat invas nsclc cell also western blot wb analysi perform assess level apoptosi epithelial mesenchym transit emt proliferation rel protein foxp protein rna immunoprecipit rip dual luciferas report assay use verifi interact mir p hsa circ foxp besid mice xenograft model construct confirm effect hsa circ nsclc tumor growth vivo hsa circ lowli express nsclc tissu cell overexpress inhibit prolifer migrat invas emt process improv apoptosi nsclc cell mir p spong hsa circ overexpress invert suppress effect overexpressed hsa circ nsclc progress moreov foxp target mir p silenc revers inhibit effect overexpressed hsa circ nsclc progress addit hsa circ overexpress reduc tumor growth nsclc vivo hsa circ spong mir p improv foxp express inhibit nsclc progress studi show hsa circ potenti biomark earli diagnosi nsclc
